← All trials
NCT03926351
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2018
- Primary completion
- Oct 31, 2019
- Completion date
- Oct 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Oslo Metropolitan UniversityLead sponsor
- Oslo Metropolitan UniversityReponsible party - principal investigator
- Oslo Metropolitan UniversityOverall official - principal investigator
- Pre Diagnostics ASCollaborator
- BASFCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.